Oncogene MYC is highly expressed in many human cancers and functions as a global regulator of ribosome biogenesis. Previously, we reported that ribosomal protein (RP) L11 binds to c-Myc and inhibits its transcriptional activity in response to ribosomal stress. Here, we show that RPL5, co-operatively with RPL11, guides the RNA-induced silencing complex (RISC) to c-Myc mRNA and mediates the degradation of the mRNA, consequently leading to inhibition of c-Myc activity. Knocking down of RPL5 induced c-Myc expression at both mRNA and protein levels, whereas overexpression of RPL5 suppressed c-Myc expression and activity. Immunoprecipitation revealed that RPL5 binds to 3 0 UTR of c-Myc mRNA and two subunits of RISC, TRBP (HIV-1 TAR RNA-binding protein) and Ago2, mediating the targeting of c-Myc mRNA by miRNAs. Interestingly, RPL5 and RPL11 co-resided on c-Myc mRNA and suppressed c-Myc expression co-operatively. These findings uncover a mechanism by which these two RPs can co-operatively suppress c-Myc expression, allowing a tightly controlled ribosome biogenesis in cells.
INTRODUCTION
The c-Myc oncoprotein is a globally regulatory factor of cell growth and proliferation. 1, 2 Deregulation of c-Myc is highly associated with a wide range of cancers. [3] [4] [5] [6] [7] [8] [9] In cancer cells, constant activation of c-Myc has a vital role in cancer development by transcriptionally regulating a number of genes that are involved in cell division, metabolic adaptation, cell survival and ribosome biogenesis. 1, 10 A number of studies have shown that amplification of MYC, the c-Myc-encoding gene, through multiple mechanisms, including chromosomal translocation and mutations, [11] [12] [13] [14] is correlated with poor clinical outcome and tumor aggression. 15, 16 Proliferation of tumor cells with high levels of c-Myc is no longer dependent on growth factor stimulation, whereas in normal cells, growth factor stimulation is required for c-Myc-dependent proliferation, metabolic pathways, cell adhesion and ribosome biogenesis. 13, 14, [17] [18] [19] [20] Thus, the role of c-Myc in controlling ribosome biogenesis and translation is crucial for the development and progression of tumors. 17 Ribosome biogenesis is essential for fast-growing cancer cells and tightly regulated in normal growing cells. In prokaryotes, free ribosomal proteins (RPs) that resulted from deregulation of ribosome biogenesis can bind to their own mRNAs and inhibit their transcription to avoid unneeded synthesis of RPs. 21 This simple mode of autoregulation of RP expression, though not yet found in eukaryotes, has evolved to a more complicated mechanism involving c-Myc in eukaryotic cells. Previously, we discovered that RPL11 binds to c-Myc and inhibits its activity. 22 Later on, RPL11 was shown to bind to c-Myc mRNA and promote its degradation by miRNAs. 23 Because c-Myc stimulates the transcription of RP-encoding mRNAs, 17, 22 RPL11 can negate c-Myc activity via a negative-feedback mechanism and consequently lead to a tightly monitored ribosome biogenesis in mammalian cells. A 'byproduct' of this negative regulation of c-Myc by free RPL11 is to prevent cell transformation, as ribosome biogenesis is usually elevated in cancer cells. 17 Indeed, free forms of several RPs, generated by unexpected ribosome biogenesis or in response to ribosomal stresses, have been identified to have important roles in preventing tumorigenesis. A number of RPs, including RPL11, [24] [25] [26] [27] RPL5, 28 RPL23, 29, 30 RPL26, 31 RPS3, 32 RPS7, 33, 34 RPS14, 35 RPS25, 36 RPS27 37 or RPS27a, 38 have been shown to suppress tumor cell growth by activating p53 in response to ribosomal stress. Although RPL11 has been shown to negatively regulate c-Myc activity independently of the MDM2-p53 pathway, 22 and also, RPL11 and RPL5 have been shown to work together to activate p53, 39 it remains largely unclear whether these p53-activating RPs could also exert their extra-ribosomal function individually or co-operatively toward c-Myc in a sub-ribosomal complex. Thus, this prompted us to determine whether RPL5 also has a role in regulating c-Myc level or activity, and if true, whether this regulation is executed by cooperating with RPL11.
In this study, we intended to address these two questions. First, we found out that RPL5 binds to c-Myc mRNA and inhibits its expression by mediating the binding of the RNA-induced silencing complex (RISC) to c-Myc mRNA. Also, we showed that RPL5 coresides with RPL11 on c-Myc mRNA and inhibits the expression of c-Myc co-operatively with the latter. Hence, our studies as detailed below demonstrate the co-operative action of these two RPs on inactivation of c-Myc by guiding the RISC to its mRNA and inhibiting its expression.
RESULTS

RPL5 inhibits c-Myc-dependent proliferation by suppressing c-Myc expression
To investigate whether c-Myc expression is affected by RPL5, we first used small-interferring RNA (siRNA) to knock down endogenous RPL5 in H1299 cells. As shown in Figure 1a , knockdown of RPL5 led to the increase of c-Myc mRNA level as determined by real-time quantitative PCR (RT-qPCR), whereas overexpression of RPL5 by transfection of a plasmid that expressed a flag-RPL5 fusion protein only caused a mild reduction of c-Myc mRNA (left, Figure 1a ). However, interestingly, after stimulating cells by 20% serum to induce c-Myc expression, overexpression of RPL5 led to the reduction of c-Myc mRNA level dramatically (right, Figure 1a ). The inhibitory effect of RPL5 on c-Myc level was also confirmed at its protein level by western blot (WB) analysis. RPL5 knockdown resulted in the elevation of c-Myc protein level that is similar to that of RPL11 knockdown (Figure 1b 18, 40, 41 we next checked whether increased RPL5 expression could affect cell proliferation by regulating c-Myc level. As shown in Figure 1c , ectopic RPL5 led to a marked decrease in BrdU (5-bromodeoxyuridine) incorporation in serum-re-stimulated H1299 cells, compared with cells without exogenous RPL5. Interestingly, the inhibitory effect of RPL5 on proliferation could be observed only in serum-re-stimulated cells, suggesting that c-Myc induction might be required for this regulation (Figure 1c ). To further determine the effect of RPL5 on c-Myc-enhanced proliferation, we performed a BrdU cell proliferation assay with c-Myc-transfected cells. As expected, c-Myc induced cell proliferation as indicated by the increase in BrdU incorporation. Again, co-expression of Flag-RPL5 in c-Myc-expressing cells resulted in the significant decline of BrdU incorporation in a dose-dependent manner (Figure 1d ). Together, these results indicate that RPL5 suppresses c-Myc expression and inhibits its activity, consequently retarding c-Myc promoted cell proliferation.
RPL5 inhibits induction of c-Myc by serum stimulation c-Myc is rapidly induced in response to serum stimulation. To determine whether this serum-responsive induction could be affected by RPL5, we compared c-Myc levels in H1299 cells transfected with RPL5, RPL11 or pcDNA vector upon serum stimulation. H1299 cells were serum-starved for 24 h and then cultured in medium containing 20% bovine serum. Cells were then harvested at different time points after serum stimulation. As expected, 23 the induction of c-Myc expression was drastically reduced in cells that overexpressed RPL11 at each time point after serum stimulation (Figure 2a ). Similarly and interestingly, overexpression of RPL5 also markedly decreased the level of endogenous c-Myc in comparison with control cells (Figure 2a ). Consistent with this result, knockdown of either of these two endogenous RPs in H1299 cells led to the induction of c-Myc mRNA levels compared with control cells (Figure 2b) . These results indicate that RPL5 also regulates c-Myc expression after serum stimulation.
Because RPL5 suppresses c-Myc mRNA expression ( Figures 1a  and 2b ) similarly to what RPL11 does, 23 and RPL11 was previously shown to target c-Myc mRNA by miRNAs, 23 we suspected that RPL5 might employ the same mechanism to inhibit c-Myc expression. First, we investigated whether disruption of the miRNA machinery would affect the regulation of c-Myc by RPL5 by knocking down TRBP (HIV-1 TAR RNA-binding protein), an important subunit of RISC, 42, 43 in H1299 cells, as TRBP knockdown was previously shown to impair the miRNA processing and silencing steps. 44, 45 Indeed, disruption of miRNA functions by TRBP knockdown rescued the inhibitory effect of RPL5 on c-Myc induction by serum stimulation, at least partially ( Figure 2c ), suggesting that miRNAs might be involved in the regulation of c-Myc by this RP. Because H1299 cells are p53 deficient, this effect is p53 independent.
RPL5 targets c-Myc 3 0 UTR We assumed that RPL5 might bind to c-Myc 3 0 UTR and thus suppress c-Myc expression by utilizing a mechanism similar to that for RPL11. 23 To test this idea, we first checked the binding of RPL5 with c-Myc mRNA in HEK 293 cells by ribonucleoprotein immunoprecipitation (RNP-IP) assay. 23, 46 As shown in Figures 3a and c, Myc mRNA, but not gapdh mRNA, was enriched more than sixfold in Flag-L5 IP samples than that in immunoglobulin (Ig)G IP samples. Also, this enrichment of c-Myc mRNA depended on RPL5 expression, for c-Myc mRNA was not enriched by the anti-flag antibody in cells without overexpression of flag-RPL5. This association between RPL5 and c-Myc mRNA was further confirmed using an HEK293 cell line that stably expresses flag-RPL5, as c-Myc mRNA was only pulled down by the flag antibody in flag-RPL5-HEK293 stable cells, but not in parental HEK293 cells ( Figure 3b ). Thus, it is likely that RPL5 can form a complex with c-Myc mRNA in cells.
Next, we tested whether RPL5 could directly target c- that RPL5, similarly to RPL11, may regulate c-Myc expression by interacting with the 3 0 UTR region of its mRNA.
RPL5 binds to the TRBP2 and Ago2 subunits of the RISC Our finding that RPL5 associates with c-Myc mRNA and targets its 3 0 UTR suggests that this RP might, similar to RPL11, 23 regulate c-Myc mRNA level by miRNA as well. To begin to test this possibility, we first determined whether RPL5 could bind to the RISC. As one of the RISC subunits, TRBP has been shown to be an essential component of this complex and have a vital role in facilitating the binding of the other two subunits of RISC, Dicer and Ago2. 42, 43 Therefore, we tested the association of RPL5 with TRBP2 by transfecting HEK293 cells with myc-TRBP2 and flag-RPL5, followed by carrying out IP-WB analysis. Interestingly, myc-TRBP2 was pulled down by anti-flag antibodies in cells expressing both flag-RPL5 and myc-TRBP2, but not in cells without flag-RPL5, indicating that RPL5 binds to TRBP2 in cells ( Figure 4a ). We also tested whether other RPs might bind to TRBP2 by performing a set of co-IP-WB experiments. As shown in Figures 4b and c, myc-TRBP2 was co-immunoprecipitated with flag-RPL11 as well, but not flag-RPL23 and flag-RPL26, suggesting that the interaction with TRBP2 is specific to RPL5 and RPL11, but not other RPs as tested here. Also, this specific interaction was not due to the . RPL5 and RPL11 interact with TRBP2 in cells. (a) RPL5 binds to TRBP2. HEK 293 cells were transfected with myc-TRBP2 and Flag-RPL5 as indicated in the figure and harvested for IP (0.5 mg total proteins) using anti-Flag, followed by IB with the antibodies as indicated. (b) RPL11 binds to TRBP2. HEK 293 cells were transfected with myc-TRBP2 and Flag-RPL11 as indicated in the figure and harvested for IP (0.5 mg total proteins) using anti-Flag or mouse IgG, followed by IB with the antibodies as indicated. (c) RPL23 and RPL26 cannot bind to TRBP2. HEK 293 cells were transfected with indicated plasmids and harvested for IP (0.5 mg total proteins) using anti-Flag, followed by IB with the antibodies as indicated. (d and e) Endogenous RPL5 and RPL11 interact with endogenous TRBP2 in HEK 293 cells. Cells lysates (0.6 mg) were prepared from HEK 293 cells after treatment with Act D for 8 h. IP was conducted with anti-TRBP2 or rabbit IgG followed by IB with anti-TRBP2 or anti-RPs. (f ) RPL5 and RPL11 also bind to Ago2. HEK 293 cells were transfected with indicated plasmids and harvested for IP (0.5 mg total proteins) using anti-HA, followed by IB with the antibodies as indicated. All the experiments were repeated more than twice and true to the rest of data. different expression levels of these proteins, as WB analysis of HEK293 cell extracts confirmed that their steady-state levels were equivalent in all of the transfected cells (Figures 4b and c) . The interaction of TRBP2 with RPL5 and RPL11 was also verified using endogenous proteins, as anti-TRBP2, but not non-specific IgG, antibodies could pull down endogenous RPL5 and RPL11 in HEK293 cells as well (Figures 4d and e ). These results indicate that RPL5 and RPL11 can bind to TRBP2 in cells. As RPL11 was previously reported to bind to another RISC subunit Ago2, 23 we also tested whether this is true to RPL5. Indeed, RPL5 was coimmunoprecipitated with Ago2 as shown in Figure 4f . Taken together, these results demonstrate that RPL5, similar to RPL11, can bind to the RISC in cells.
RPL5 mediates the binding between RISC and c-Myc 3 0 UTR Our findings that RPL5 binds to RISC subunits and c-Myc mRNA via its 3 0 UTR suggest that RPL5 might mediate the association of RISC with c-Myc 3 0 UTR. To test this idea, we performed an RNP-IP assay by introducing myc-TRBP2 with flag-L5 or pcDNA3 control plasmid into HEK293 cells. Then, RNP complexes were immunoprecipitated from cell lysates using an antibody against myc-TRBP2. Subsequently, RNA was extracted, reverse-transcribed and subjected to RT-qPCR with primers for c-Myc mRNA. As shown in Figure 5a , the c-Myc transcript level as immunoprecipitated in the complex was significantly increased in the presence of flag-RPL5 compared with the pcDNA3 control, suggesting that RPL5 may promote the binding of TRBP2 to c-Myc mRNA.
As TRBP2 was previously reported to be essential for miRNA functions, 44, 45 we examined whether TRBP2 is required for RPL5 regulation of c-Myc expression in cells. Indeed, this was the case as siRNA-mediated silencing of TRBP2 expression in H1299 cells abrogated the inhibitory effect of RPL5 on c-Myc expression ( Figure 5b ). To check whether RPL5 is required for the binding of TRBP2 to c-Myc mRNA, we carried an RNP-IP assay after knocking down endogenous RPL5 by siRNA. As expected, RPL5 knockdown impaired the binding of TRBP2 to c-Myc mRNA (Figure 5c ). Consistent with this result, knockdown of RPL5 by siRNA abrogated the inhibitory effect of overexpressed miR-145 on c-Myc expression, as in the absence of RPL5 siRNA, ectopically expressed miR-145 led to the marked decrease of endogenous c-Myc in H1299 cells as determined by WB (Figure 5d ). Taken together, these results suggest that RPL5 can act as a mediator for the targeting of c-Myc mRNA by miR-145-quided RISC.
RPL5 and RPL11 inactivate c-Myc co-operatively As both RPL5 and RPL11 had been shown to protect each other from degradation 47 and to stimulate p53 co-operatively, 39 we would like to test whether RPL5 might also cooperate with RPL11 to inhibit c-Myc mRNA expression by miRNAs. To this end, we first carried sequential RNP-IP to examine whether these two RPs could simultaneously interact with c-Myc mRNA. Flag-RPL5, GFP-RPL11 and c-Myc 3 0 UTR were co-expressed in HEK293 cells, and their expression was confirmed by WB (right, Figure 6a ). Sequential RNP-IP analysis was then performed with anti-flag antibodies for the first IP to pull down flag-RPL5 followed by secondary IP with anti-GFP antibodies to pull down GFP-RPL11 after eluting the RPL5-associated complexes with flag peptides. Then the captured GFP-RPL11-and Flag-RPL5-containing complexes were used for RNA extraction, which was used for RT-qPCR assays. As shown in Figure 6a , an approximately sevenfold enrichment in c-Myc 3 0 UTR, but not gapdh mRNA, was clearly evident in the complexes, demonstrating that RPL5 and RPL11 do co-interact with c-Myc mRNA.
Next, we tested whether RPL5 and RPL11 act co-operatively to inhibit c-Myc expression by miRNAs. To determine whether RPL11 is required for the inhibitory effect of RPL5 on c-Myc expression, RPL11 gene expression in H1299 cells was silenced using siRNA methodology. As expected, RPL11 siRNA transfection decreased the level of endogenous RPL11; interestingly, this decrease of RPL11 level impaired the inhibitory effect of RPL5 on c-Myc expression as determined by WB (Figure 6b) . Similarly, RPL5 knockdown also impaired the declining of c-Myc level by RPL11 (Figure 6c ). These findings suggest RPL5 and RPL11 need each other to regulate c-Myc level in cells. To further determine whether they could co-operatively help each other, we introduced different amounts of flag-RPL5 or flag-RPL11 expression vectors in H1299 cells and monitored the c-Myc level by WB. Indeed, although c-Myc protein level was not obviously affected by each of these RPs alone at lower concentrations (lane 2 and 4, Figure 6d ), co-expression of RPL5 and RPL11 at the same levels significantly reduced the expression of c-Myc (lane 5, Figure 6d ), indicating that the two RPs could cooperate with each other in inhibiting the expression of c-Myc. Because RPL5 and RPL11 can form a complex by 5S rRNA, we tested whether this association is essential for their co-operative effect on c-Myc expression by employing a mutant RPL11, R75Q, as this mutant was defective in binding to 5S rRNA and RPL5. 39 As expected, GFP-RPL11 bound to flag-RPL5 in an RNase-dependent fashion (Figure 6e ). Also, flag-RPL11 bound to endogenous RPL5, whereas flag-RPL11 R75Q failed to do so (Figure 6f ). To determine whether the binding between RPL5 and RPL11 is essential for the regulation of c-Myc expression, we knocked down RPL11 and investigated whether RPL5 or RPL11 R75Q mutant can prevent the c-Myc induction by knocking down endogenous RPL11. As shown in Figure 6g , overexpression of ectopic RPL5 failed to do so (lane 1-4). This result, consistent with the above results, again indicates that RPL11 is required for the targeting of c-Myc by RPL5. Interestingly, co-overexpressing ectopic wild-type RPL11, but not its mutant R75Q, with RPL5 reversed the RPL11 depletion-induced c-Myc expression ( Figure 6g ). These results confirm that the binding between RPL5 and RPL11 is essential for this regulation. In summary, these results indicate that RPL5 and RPL11 cooperatively suppress the expression of c-Myc by RISC.
DISCUSSION
c-Myc overexpression is highly associated with tumorigenesis, which is at least partially because of the global deregulation of ribosomal biogenesis. 17 Previously, we showed that RPL11 inhibits c-Myc activity through direct binding to c-Myc protein. 22 Later on, this protein was found to also suppress c-Myc activity by recruiting miRNAs to c-Myc mRNAs. 23 These findings indicate the existence of the autoregulation of c-Myc by some of its downstream transcriptional target genes that encode RPs. Our study, as presented here, identified RPL5 as another regulator of c-Myc. Moreover, RPL5 can cooperate with RPL11 in suppressing the expression of c-Myc through a RISC-mediated miRNA-targeting mechanism. First, we showed that RPL5 suppresses the expression of c-Myc and consequently inhibits proliferation induced by this oncoprotein (Figure 1 ). Interestingly, we found that TRBP, one of the RISC components, is critical for this inhibition by RPL5, as knocking down TRBP partially rescued the inhibitory effect of RPL5 on c-Myc induction in response to serum stimulation (Figure 2) . Also, RPL5 facilitated the targeting of c-Myc mRNA by miRNAs, such as mi-R145, by binding to c-Myc mRNA and two RISC subunits, TRBP and Ago2 (Figures 3-5 ). This binding to RISC appears specific to these two RPs, as neither RPL23 nor RPL26 could bind to this complex (Figure 4c ). Finally, we uncovered that RPL5 and RPL11 form a complex with c-Myc mRNA, acting together to repress c-Myc expression in a co-operative fashion ( Figure 6 ). These results demonstrate that RPL5 and RPL11 are the two partners that act as critical feedback regulators of c-Myc during ribosomal biogenesis. These two RPs have also been previously shown to work together in activating p53 by cooperatively inhibiting the activity of the MDM2 oncoprotein. 39 Our study that recapitulated their co-operative effect on another oncoprotein c-Myc further validates the notion that RPL5 and RPL11 can indeed work as one complex in cells to control cell proliferation and growth (Figures 1-6 ), although it remains unclear why eukaryotic cells utilize two, instead of one, RPs to control c-Myc activity.
Interestingly, our finding also presents an evolutionarily conserved molecular mechanism underlying the feedback regulation of ribosomal biogenesis. In prokaryotes, in response to ribosomal stress or shortage of complementary rRNA, RPs could bind to their own mRNA and repress RP synthesis. 21 This negative-feedback loop of RPs and their mRNAs has a vital role in fine-tuning of ribosome biogenesis in prokaryotic cells. Although this simple autoregulatory feedback circuit of ribosomal biogenesis has not yet been reported thus far in eukaryotes, this mechanism is resembled by the feedback regulation of c-Myc level and activity by RPL11 and RPL5, as the genes encoding both of the RPs are the transcriptional targets of c-Myc. Different from the prokaryotic mechanism, these eukaryotic RPs target c-Myc mRNA, instead of their own mRNAs, to execute their inhibitory action of c-Myc through a more complicated and RISC-mediated mechanism. Through this unique and sophisticated mechanism, ribosomal biogenesis is finely tuned so that no excess amounts of RPs would be produced under normal growth conditions, as extra amounts of these proteins would also be toxic to cells by activating the p53 pathway. [48] [49] [50] [51] A number of RPs have been shown to activate p53 by inhibiting MDM2-induced polyubiquitination of p53 in response to ribosomal stresses. [24] [25] [26] [27] [28] [29] [30] [31] [33] [34] [35] 37, 38 However, how free RPs act in p53-null cells is still largely unknown. Here, we show that RPL5 can suppress c-Myc expression by targeting its mRNA by RISC and miRNA independently of the p53 pathway (Figures 1-5 ). Together with RPL11, RPL5 among all of the MDM2-interacting RPs 22, 23 might have a more important role in preventing neoplasia by acting on both of the p53 and c-Myc pathways important in tumor development and progression. Indeed, both of RPL11 and RPL5 have been shown to negate tumor growth in genetic studies. [48] [49] [50] [51] The negative action of RPL5 and RPL11 on c-Myc and MDM2 could be utilized as a strategy for the development of anticancer therapy in the future.
MATERIALS AND METHODS
Cell lines, plasmids and antibodies
Human HEK293 and H1299 cells were cultured in Dulbecco's-modified Eagle's medium supplemented with 10% fetal bovine serum, 50 U/ml penicillin and 0.1 mg/ml streptomycin at 37 1C in a 5% CO 2 -humidified atmosphere. RPL5, RPL11, RPL23, RPL26, TRBP and c-Myc expression plasmids were described previously. 28, 29, 43, 52 RPL11 mutant R75Q plasmids was a gift from Dr Vousden. 39 c-Myc 3 0 UTR was amplified from HCT116 cells and inserted into pMIR reporter vector. The primers used were: P1: 5 0 -GGACTAGTTCTCAGAGGCTTGGCGGGAAAAAGA-3 0 and P2: 5 0 -CCCAAGCT TGGCTCAATGATATATTTGCCAGTTA-3 0 . Anti-L5 28 and anti-L11 22 have been previously described. Anti-Flag (Sigma, Rehovot, IL, USA), anti-c-Myc (N262, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-actin (Sigma), anti-BrdU (IIB5, Santa Cruz Biotechnology), anti-TRBP2 (1D9, LifeSpan Biosciences, Inc., Seattle, WA, USA), anti-HA (F-7, Santa Cruz Biotechnology) and anti-myc (9E10, Santa Cruz Biotechnology) were commercially purchased.
Transient transfection, WB and co-IP analyses As described previously, 53 briefly, cells were transfected with indicated plasmids as shown in each figure by using TransFectin (Bio-Rad, Hercules, CA, USA), following the company's instruction. Unless specifically mentioned, 48 h post transfection, cells were harvested and lysed in lysis buffer. The total protein concentration for each sample was determined and equal amount of total proteins were then subjected to SDS-polyacrylamide gel electrophoresis, followed by WB. IP was conducted by using antibodies as indicated in the figure legends and described previously. 54 Beads were washed three times with lysis buffer. Bound proteins were detected by immunoblot (IB) with antibodies as indicated in the figure legends.
Reverse transcription and RT-qPCR analysis
Reverse transcription and RT-qPCR for mRNAs were done by using the methods described previously. 28, 55 Briefly, RT-qPCR was performed on an ABI 7300 real-time PCR system (Applied Biosystems, Foster City, CA, USA) using SYBR Green Mix (Applied Biosystems). Relative gene expression was calculated using the DC T method, following the manufacturer's instruction. All reactions were carried out in triplicate.
Luciferase reporter assays
Cells were transfected with pMIR-c-Myc-3 0 UTR and indicated plasmids (total plasmid DNA 1 mg/well) as indicated in figures. Luciferase activity was determined and normalized by a factor of b-gal activity in the same assay as described previously. 56 
RNP-IP assay
The RNP-IP assay was performed as described previously 23 using anti-flag, anti-myc, or anti-GFP for ectopic proteins. Immunoprecipitated RNAs were extracted and analyzed by RT-qPCR amplification using primers for c-Myc.
BrdU incorporation assays
BrdU incorporation assays were carried out by basically following the previously described protocol. 55 Cells were incubated in the presence of 10 mM of BrdU for 5 h. Cells were then fixed with 95% of ethanol and 5% of acetic acid, treated with 2 M HCl containing 1% Triton X-100 and stained with the monoclonal anti-BrdU antibody, followed by staining with Alexa Fluor 546 (red) goat anti-mouse antibodies and 4 0 ,6-diamidino-2phenylindole, dihydrochloride (DAPI). Stained cells were analyzed under a Zeiss Axiovert 25 fluorescent microscope Carl Zeiss, Oberkochen, Germany.
Knockdown of the endogenous mRNAs siRNAs for RPL5 and RPL11 were described previously. 22,28 siRNA for TRBP was purchased from Santa Cruz Biotechnology. Transfection of siRNAs were performed the same as that of normal siRNA as described previously 57 by using siLentFect Lipid (Bio-Rad), following the manufacturer's protocol.
